Plexium

This week, the Plexium team is in Boston at the Proteomics Based Drug Discovery Summit.?On Tuesday, February 11, 2025, at 9:30 am ET, Alex Campos will participate in a panel discussion focused on this exciting field of research, including how to generate high-quality data, how to leverage the latest advancements in robotic systems for automation, and how to optimize workflows to improve data analysis.?Learn more here: https://lnkd.in/gGJW5MU9 We hope to see you there! #ProteomicsDrugDiscovery2025 #DrugDiscovery

Next week, Kevin Freeman-Cook, Ph.D., our VP of Chemistry, will be attending the Medicinal & Bioorganic Chemistry Foundation’s (MBCF) 17th Winter Conference. On Monday, February 3rd, he will chair the session Leveraging Chemically Induced Proximity in Drug Discovery. Dr. Freeman-Cook will be joined by Geoffray Leriche, Principal Scientist, as well as other industry leaders in this exciting space.?Geoffray will discuss the discovery of orally bioavailable SMARCA2-Selective monovalent degraders. Learn more here: https://lnkd.in/gpwHmJzQ #Biotech #DrugDiscovery #Pharma #MBCF2025

This week, Peggy Thompson, Ph.D., our VP of Biology, will speak at the 3rd Molecular Glue Drug Development Summit in Boston, MA. Starting on Wednesday, she’ll discuss turbocharging molecular glue design by focusing on proteins of interest, followed by a panel discussion on Thursday. Learn more here: https://lnkd.in/g_qYwSZA #Biotech #DrugDiscovery #Pharma #MolecularGlue

“I am excited to be speaking at the 3rd Molecular Glue Drug Development Summit! I hope you can join me there. Follow this link to find out more:https://lnkd.in/g96W5VUt?"?

We are thrilled to welcome Jorge DiMartino M.D., Ph.D., as our Chief Medical Officer and Executive Vice President of Clinical and Translational Development. Dr. DiMartino is a physician-scientist with more than 20 years of experience in early clinical development and clinical proof-of-concept in biotech and large pharmaceutical settings, including key roles at Kronos Bio, Celgene, and Genentech. Dr. DiMartino will be responsible for leading Plexium’s clinical function and overseeing the advancement of development stage programs against high-value targets such as SMARCA2, IKZF2, CDK2, CRAF, and others. Read more here: https://lnkd.in/gxRXtWpv #Biotech #DrugDiscovery #Pharma #Leadership

Later this week, Michael Martin, Ph. D., our CEO, and Stephen Mullennix, our CFO, will participate in the UBS Virtual Biotechnology Private Company Symposium and engage with investors in virtual one-on-one meetings. Learn more about Plexium here: https://www.plexium.com/ #UBSBiotechSymposium #Biotech #DrugDiscovery #Pharma

Next week, Michael Martin, Ph. D., our CEO, and Stephen Mullennix, our CFO, will head to New York to participate in the Cantor Fitzgerald Global Healthcare Conference and engage with investors in one-on-one meetings. Learn more here: https://lnkd.in/epSG4nTh #CantorGlobalHealthcare #Biotech #DrugDiscovery #Pharma

Tomorrow, Thursday, September 5th, Stephen Mullennix, our Chief Financial Officer, is attending the Morgan Stanley 22nd Annual Global Healthcare Conference and will be participating in one-on-one meetings with investors during the conference. #Biotech #DrugDiscovery #MorganStanley2024

Kevin Freeman-Cook, PhD, our VP of Chemistry, will present in the first disclosure session at the upcoming American Chemical Society (ACS) Fall Meeting, focusing on the discovery of PLX-4545, a molecular glue degrader of IKZF2. The meeting will take place in Denver, CO, and virtually, on August 18-22, 2024. Learn more here: https://lnkd.in/eZbQiH5j #biotech #drugdiscovery #drugdesign #pharma #ACSfall2024

We are pleased to share that Kevin Freeman-Cook, PhD, our VP of Chemistry, is presenting at the Medicinal Chemistry GRC Conference. The meeting will take place from August 11 to 16 in New London, NH. More information can be found here: https://lnkd.in/eunNmF9q #biotech #drugdiscovery #drugdesign #pharma #GRC2024